Current therapy for seronegative arthritides (Spondyloarthritis)

Bulletin of the NYU Hospital for Joint Diseases

Volumn 69, Issue 3, 2011, Pages 250-252

  Dougados, Maxime ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALENDRONIC ACID; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; RITUXIMAB; SALAZOSULFAPYRIDINE;

ANKYLOSING SPONDYLITIS; ARTICLE; CARDIOTOXICITY; DISEASE COURSE; DRUG MEGADOSE; ENTERITIS; ENTHESOPATHY; GASTROINTESTINAL TOXICITY; HUMAN; PHYSICAL ACTIVITY; PSORIASIS; SPONDYLOARTHROPATHY; UVEITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHYSICAL THERAPY MODALITIES; SPONDYLARTHRITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054098384     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Zeidler H, Amor B. The assessment in spondyloarthritis international society (ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress. Ann Rheum Dis. 2011;70(1):1-3.
2. Dougados M, Baeten D. Recent advances in spondyloarthritis. Lancet. 2011 (inpress).
3. Braun J, van den Berg R, Baraliakos C, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896-904.
4. Dougados M. Les Rhumatismes en 100 questions. Available at: www.rhumatismes.net. Accessed July 15, 2011.
5. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65:316-20.
6. Dagfinrud H, Hagen KB, Kvien TK. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database of Systematic Reviews 2008, issue 1, art. no.: CD002822. DOI: 10.1002/14651858.CD002822.pub3.
7. Benhamou M, Gossec L, Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/Coxibs' treatment effect on C-reactive protein. Rheumatology (Oxford). 2010;49:536-41.
8. Poddubnyy D, Haibel H, Listing L, et al. Influence of NSAID intake on the radiographic spinal progression over 2 years in patients with early axial spondyloarthritis. Ann Rheum Dis. 2011;abstr. OP0177.
9. Wanders A, van der Heijde D, Landewé R, et al. Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52:1634-6.
10. Maugars Y, Mathis C, Berthelot JM, et al. Assessment of the efficacy of sacroiliac corticosteroid injections in spondyloarthropathies: a double blind study. Br J Rheumatol. 1996;35(8):767-70.
11. Dougados M, Boumier P, Amor B. Treatment of ankylosing spondylitis with salazosulfapyridine: a controlled double blind study in 60 patients. Br Med J 1986;293(6552):911-4.
12. Kang JH, Chen YH, Lin HC. Comorbidity profiles among patients with ankylosing spondylitis: a nationwide populationbased study. Ann Rheum Dis. 2010;69:1165-8.
13. Braun J, Horst-Bruisma IE, Huang F, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized double blind trial. Ann Rheum Dis. 2011;63(6):1543-51.
14. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(6):905-8.
15. Haibel H, Sieper J. How early should ankylosing spondylitis be treated with a tumor necrosis factor blocker? Curr Opin Rheumatol. 2010;22(4):388-92.
16. Dougados M, Braun J, Szanto S, et al. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: Results of a randomized double blind placebo- controlled study (SPINE). Ann Rheum Dis. 2011;70(5):799-804.
17. Maksymowych WP, Jhangri GS, Fitzgerald AA, et al. A six month randomized controlled double-blind dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of non steroidal anti-inflammatory drug refractory ankylosing spondylitis. Arthritis Rheum. 2002;46(3):766-73.
18. Coates L, Bhalla A, Creamer P, et al. The effect of alendronate on ankylosing spondylitis: the results of the bisphosphonates in ankylosing spondylitis trial (BIAS). Ann Rheum Dis. Suppl. EULAR 2011;abstr OP0176.
19. van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58:3063-70.
20. van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11:R127.
21. Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label 24 week pilot study. Ann Rheum Dis. 2011;70(6):1108-10.
22. Del Castillo Pinol N, Gossec L, Sparsa L, et al. Tocilizumab for treatment of refractory spondyloarthropathies: Report of 5 cases. Ann Rheum Dis. Suppl. EULAR 2011;abstr. THU0493.
23. Dudler J, Aubry-Rozier B. Tocilizumab in axial spondyloarthropathies: Report of 18 cases. Ann Rheum Dis. Suppl EULAR 2011;abstr. OP0178.
24. Baeten D, Sieper J, Emery P, et al. The anti-IL17A monoclonal antibody secukinumal (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Ann Rheum Dis. Suppl EULAR 2011;abstr. OP0174.
25. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of Tumor Necrosis Factor alpha. N Engl J Med. 2002; 346(18)1349-56.
26. Dougados M, Combe B, Braun J, et al. A randomized multicentre double-blind placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL study. Ann Rheum Dis. 2010;69(8):1430-5.